Perspective Therapeutics, Inc. Forecasted to Earn FY2024 Earnings of ($0.12) Per Share (NYSEAMERICAN:CATX)

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research note issued to investors on Monday, May 6th. Lifesci Capital analyst A. Dhankher expects that the company will post earnings per share of ($0.12) for the year. Lifesci Capital has a “Outperform” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.09) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($0.14) EPS.

CATX has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and set a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st. B. Riley upped their target price on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Finally, Cantor Fitzgerald initiated coverage on shares of Perspective Therapeutics in a research note on Thursday. They set an “overweight” rating on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of 1.53.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at 1.76 on Thursday. Perspective Therapeutics has a 52 week low of 0.21 and a 52 week high of 1.90. The firm has a market cap of $1.03 billion, a PE ratio of -17.60 and a beta of 1.43. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CATX. ZWJ Investment Counsel Inc. acquired a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $26,000. Simplicity Wealth LLC bought a new stake in Perspective Therapeutics in the 1st quarter valued at $40,000. Bleakley Financial Group LLC bought a new stake in Perspective Therapeutics in the 1st quarter valued at $40,000. Bank of New York Mellon Corp acquired a new position in Perspective Therapeutics in the 3rd quarter worth $42,000. Finally, RIA Advisory Group LLC lifted its holdings in shares of Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.